In this tutorial, we explore the design, execution, and regulatory use of bracketing studies in the context of shelf life extension submissions.

What Are Bracketing Studies?

Bracketing is a type of reduced stability design defined in ICH Q1D. It involves selecting only the extremes (highest and lowest strengths or container sizes) for stability testing, under the assumption that intermediate configurations will behave similarly.

This strategy is most applicable when products:

• Have identical formulation across all strengths or fills
• Use the same container-closure system
• Follow uniform manufacturing processes

For more foundational insights on such reduced designs, you can visit GMP guidelines covering stability testing strategies.

When to Use Bracketing for Shelf Life Extensions

Bracketing can be used in shelf life extension studies when:

• ✅ You aim to extend shelf life across multiple strengths or package sizes
• ✅ You have prior stability data from extremes (e.g., smallest and largest fills)
• ✅ Your goal is to reduce cost without repeating full studies on all variants

However, justification must be scientifically sound and accepted by regulatory agencies.

Designing a Bracketing Stability Study

Key considerations include:

1. Determine Extremes

• Identify lowest and highest drug strengths (e.g., 5 mg and 40 mg)
• Consider fill volume extremes (e.g., 5 mL and 100 mL vials)

2. Ensure Uniformity

Formulation, container-closure, and manufacturing process must be the same across all versions to justify bracketing.

3. Plan Testing Matrix

Only test the extreme configurations under standard ICH conditions like:

• 25°C / 60% RH – Long-term
• 30°C / 65% RH or 30°C / 75% RH – Intermediate
• 40°C / 75% RH – Accelerated

Regulatory Documentation and CTD Placement

Bracketing studies used for shelf life extension must be documented in:

• Module 3.2.P.8.1: Stability Summary
• Module 3.2.P.8.3: Justification for Reduced Design
• Module 3.2.R: Full data tables and graphs

Be sure to include rationale for not testing intermediate strengths, backed by data from past studies or supportive scientific literature.

Sample Bracketing Protocol Format

Below is a simplified format for a bracketing study used in shelf life extension:

Intermediate strengths like 10 mg and 20 mg are excluded from testing based on justified equivalence.

Case Example: Cost Savings Through Bracketing

Consider a company manufacturing a drug product in 4 different strengths. Without bracketing, testing all variants under ICH conditions could cost over ₹20 lakh annually. By applying bracketing and testing only the 5 mg and 40 mg versions, they reduced testing load by 50% and saved both cost and time in submission preparation.

This approach was accepted by EMA after providing prior study references and scientific rationale.

Common Reviewer Questions and How to Address Them

Agencies may raise queries like:

• How were bracketing extremes selected?
• Is there any variability in formulation or container systems?
• Why are intermediate strengths not tested?
• What evidence supports this equivalence assumption?

Be ready with a scientific justification report and historical data. Include forced degradation and in-process data for added robustness. Templates for such responses are available at Regulatory Compliance Portal.

Applicability to Packaging Changes

Bracketing is also suitable when packaging changes involve:

• Same material but different sizes (e.g., 30 mL vs. 100 mL PET bottles)
• Primary container remains constant, secondary varies
• Same sealing or closure mechanism

However, any change in permeability or container interaction must be tested separately.

Best Practices for Bracketing-Based Submissions

• Use trend analysis with regression for each tested configuration
• Provide protocol and statistical rationale in the dossier
• Include a summary table comparing bracketing vs. full testing
• Ensure alignment with internal SOPs for stability studies

Also, incorporate the bracketing design into your Annual Product Review and change control systems for traceability.

Advantages and Limitations

Advantages:

• Significant cost and time savings
• Scientifically robust if justified properly
• Efficient submission preparation

Limitations:

• Not suitable for different formulations or processes
• Agencies may request additional justification or data
• Requires experienced statistical and regulatory staff

Conclusion

Bracketing studies present a valuable opportunity for pharmaceutical companies to optimize stability programs and streamline shelf life extension submissions. With sound scientific design, thorough documentation, and transparent communication with regulatory bodies, bracketing can be a powerful tool for cost-effective compliance. As expectations evolve, regulatory professionals must stay updated on bracketing best practices and integrate them into routine development and lifecycle management strategies.

References:

• ICH Q1D Guideline
• Stability Testing Guidelines
• CTD Regulatory Submission Tools
• Bracketing Study SOPs
• Validation of Stability Protocols

Understanding Bracketing and Matrixing

Bracketing is a study design where only the extremes of certain factors (e.g., strengths, container sizes) are tested, assuming the stability of intermediate levels is represented by the extremes.

Matrixing involves testing a subset of the total number of samples at specific time points. Different samples may be tested at different time intervals.

Both approaches aim to minimize resource usage while maintaining sufficient data for shelf life justification.

When to Use Bracketing in Shelf Life Prediction

Bracketing is most applicable when a product is available in multiple:

• Strengths (e.g., 5 mg, 10 mg, 20 mg)
• Fill volumes (e.g., 10 mL, 30 mL)
• Container closure sizes or types

If it can be demonstrated that the extremes represent a worst-case, intermediate levels may not need to be tested. For example, if a 5 mg and a 20 mg tablet are tested, a 10 mg tablet may be bracketed.

Regulatory justification must include evidence that:

• ✅ All strengths are manufactured using the same process
• ✅ Composition is proportionally similar
• ✅ Packaging materials and configurations are consistent

Such justification should be included in your submission’s stability protocol section (Module 3.2.P.8).

Matrixing for Time Point Optimization

Matrixing allows reduced testing by omitting some time points for certain sample combinations. Consider this layout:

With matrixing, you must still ensure enough data is available to detect degradation trends and justify expiry. Statistical justification is required to ensure variability is covered across batches and conditions.

Regulatory Expectations and Documentation

To justify bracketing or matrixing in shelf life predictions, you must document:

• ✅ The rationale for design selection
• ✅ Scientific justification for omitting samples or time points
• ✅ Process comparability data
• ✅ Historical data showing worst-case selection validity

The USFDA expects a full explanation and may ask for confirmation data in post-approval commitments. For support, refer to regulatory submission guidance.

Statistical Considerations in Design

Statistical models must still be applied to the reduced dataset. This includes:

• Regression analysis using ICH Q1E principles
• One-sided 95% confidence interval calculations
• Validation of pooling if multiple batches are bracketed or matrixed

Failure to apply proper statistical treatment may result in IRs or shortened shelf life assignment by health authorities.

Case Study: Bracketing Justification in ANDA Filing

A company submitted an ANDA for a product in 5 mg, 10 mg, and 20 mg strengths. Stability data was only presented for the 5 mg and 20 mg strengths. The justification for bracketing was accepted because:

• ✅ All strengths shared the same excipient ratio
• ✅ Tablets were manufactured using identical unit operations
• ✅ Same primary packaging was used

FDA approved the shelf life based on the bracketing data, with a commitment for post-approval verification at 10 mg strength.

Practical Tips for Implementing Bracketing and Matrixing

• ✅ Discuss design proposals with the regulatory affairs team in advance
• ✅ Document product and packaging comparability thoroughly
• ✅ Use spreadsheets or statistical tools to track matrix coverage
• ✅ Include a fallback plan in case regulators reject the reduced design

Engaging QA in the review of the proposed design helps ensure compliance with GMP requirements.

Limitations of Bracketing and Matrixing

These strategies are not applicable in all situations. Avoid them when:

• ❌ Drug product degradation is nonlinear or poorly understood
• ❌ Process variability is high
• ❌ Stability is sensitive to packaging differences
• ❌ No prior data supports the assumptions made

In such cases, full design testing is warranted until trends are characterized.

SOP and Protocol Integration

Bracketing and matrixing should be predefined in your stability study protocol. Your SOPs must include:

• Eligibility criteria for applying reduced designs
• Documentation requirements and review responsibilities
• Statistical validation rules for matrix datasets
• Provisions for expanding testing in case of OOS/OOT results

Refer to SOP writing in pharma for guidance on integrating these into your site quality systems.

Summary of Justification Strategies

Conclusion

Bracketing and matrixing are not just cost-saving techniques—they are scientifically defensible strategies when used within defined boundaries. By aligning these reduced designs with ICH Q1D, FDA expectations, and sound statistical logic, you can justify shelf life predictions while maintaining compliance and efficiency.

References:

• ICH Q1D: Bracketing and Matrixing Designs
• FDA Guidance on Stability Studies
• CDSCO Stability Testing Guidance
• EMA Guidelines on Reduced Stability Design